Abstract 1590P
Background
The LEGACy project aims to improve personalized medicine for gastric cancer in EU and LATAM populations. A hospital-based registry was implemented to compare these populations as a potential tool to plan prevention and treatment strategies providing real-world data.
Methods
A retrospective observational cohort design was used. Survival estimates were determined using actuarial Kaplan-Meier curves. Comparison was performed with the loge-rank test, and differences were considered statistically significant for P values .05.
Results
A total of 689 patients diagnosed with GC from 11/2018 to 04/2021 were included. Country and clinical characteristics are shown in the table. Both cohorts had the body as the most common site reported (34.4% for EU and 51% for LATAM). The most used method for staging was computed tomography for both cohorts, but 6.9% of the LATAM population had a PET/TC instead. The staging at diagnose for LATAM was lower than for the EU population (2.8% and 17.4% respectively). Intestinal histological subtype was the most common (41.9% and 46.3% reported by EU and LATAM), while diffuse subtype was 44.9% for LATAM and 21.3% for EU population. Among patients tested for HER2, 12.5% were positive in the EU cohort and 13.8% in the LATAM cohort. For both cohorts, the most common site of HER2 positive was the GOJ. Surgery was reported in 43.4% of EU population and 48.9% in the LATAM cohort. Systemic treatment with curative intention was indicated in 50.7% in the EU cohort and 46.4% of the LATAM cohort. The most frequent scheme indicated was platinum-based (42.6% and 84.8% for EU and LATAM). Considering both cohorts only 14.4% of the patients got a 2° line of treatment and 3% of the patients received a 3° line. After using cox regression analysis, no difference in overall survival was reported, with a median of 10.9 months.
Table: 1590P
Characteristic | EU Cohort (n: 407) | LATAM Cohort (n: 282) |
Age - Median y [IQR] | 70.50 [61.00, 78.00] | 63.00 [53.00, 71.00] |
Sex - n (%) | ||
Male | 243 (59.9%) | 166 (59.1%) |
Country - n | ||
Argentine | 67 | |
Chile | 112 | |
Mexico | 70 | |
Netherlands | 159 | |
Paraguay | 31 | |
Portugal | 124 | |
Spain | 121 | |
ECOG n (%) | ||
0 | 45 (21.1%) | 61 (27.7%) |
1 | 110 (51.6%) | 116 (52.7%) |
≥2 | 47 (22.1%) | 43 (19.9%) |
Conclusions
Although the limitations of hospital-based registry analysis, this study have provided valuable insights into clinical characteristics and treatment approaches of EU and LATAM populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
European Union’s Horizon 2020.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1655P - Nampt inhibitors re-sensitize MAP17 expressing pancreas tumors
Presenter: Julia Martinez Perez
Session: Poster session 22
1656P - Targeting NPC1L1 rescues anti-tumor immunity and improves immunotherapeutic efficacy in pancreatic cancer
Presenter: Houjie Liang
Session: Poster session 22
1657P - Understanding the role of SAGA and mediator in the resistance to Pdk1 deletion in PDAC
Presenter: Katarina Ondrejkova
Session: Poster session 22
1658P - Molecular subtyping of familial pancreatic ductal adenocarcinoma identifies novel pathogenic germline variants
Presenter: Julie Earl
Session: Poster session 22
1659P - The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
Presenter: Octave Letissier
Session: Poster session 22
1660P - Squalene epoxidase promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signalling pathway
Presenter: Ruiyuan Xu
Session: Poster session 22
1661P - Precision medicine for pancreatic cancer: A clinical study validating EUS biopsies
Presenter: Joanne Lundy
Session: Poster session 22
1662P - Targeting stress granule formation as a synthetic lethality strategy for kras-induced pancreatic cancer initiation
Presenter: Patricia Santofimia
Session: Poster session 22
1663P - Role of next-generation sequencing somatic assays in patients with advanced pancreatic cancer
Presenter: Rafaela Naves
Session: Poster session 22
1664P - Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort
Presenter: Michele Reni
Session: Poster session 22